Literature DB >> 1544753

Risk factors for epithelial ovarian cancer in Beijing, China.

Y Chen1, P C Wu, J H Lang, W J Ge, P Hartge, L A Brinton.   

Abstract

A study in Beijing, China of 112 pathologically confirmed epithelial ovarian cancer cases and 224 age-matched community controls enabled evaluation of risk in relation to reproductive, medical, familial, and selected lifestyle factors. An inverse relationship was observed between the number of full-term pregnancies and ovarian cancer risk. Compared to nulliparous women, subjects with one, two, or three full-term pregnancies were at 50%, 70%, or 90% reduced risks, respectively (P for trend less than 0.01). A positive correlation was found between the number of ovulatory years and risk, with a 2.6-fold increased risk for women with 30 or more compared to less than 10 ovulatory years (P for trend less than 0.01). Infertility, as estimated in various ways, was also found to be an important risk factor. When parity was taken into account, age at first pregnancy was not related to ovarian cancer risk. No protective effect was associated with mumps virus infection. In contrast, risk increased significantly as serum mumps virus antibody titres increased (P for trend less than 0.01). An elevated risk was found in women with a history of long-term (greater than 3 months) application of talc-containing dusting powder to the lower abdomen and perineum (Relative risk 3.9, 95% confidence interval: 0.9-10.63). These findings suggest that Chinese women have risk factors similar to those of occidental women.

Entities:  

Keywords:  Age Factors; Antibodies; Asia; Biology; Cancer; Case Control Studies; China; Contraception; Contraceptive Methods; Control Groups; Demographic Factors; Developing Countries; Diseases; Eastern Asia; Family Planning; Fertility; Fertility Measurements; Immunity; Immunologic Factors; Infertility; Matched Groups; Methodological Studies; Neoplasms; Nulliparity; Oral Contraceptives; Ovarian Cancer; Ovulation; Parity; Physiology; Population; Population Characteristics; Population Dynamics; Pregnancy; Reproduction; Research Methodology; Risk Factors; Studies; Viral Diseases

Mesh:

Year:  1992        PMID: 1544753     DOI: 10.1093/ije/21.1.23

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  26 in total

1.  Breastfeeding and ovarian cancer risk: a meta-analysis of epidemiologic studies.

Authors:  Nan-Nan Luan; Qi-Jun Wu; Ting-Ting Gong; Emily Vogtmann; Yong-Lai Wang; Bei Lin
Journal:  Am J Clin Nutr       Date:  2013-08-21       Impact factor: 7.045

2.  Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium.

Authors:  Holly R Harris; Ana Babic; Penelope M Webb; Christina M Nagle; Susan J Jordan; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Francesmary Modugno; Roberta B Ness; Kirsten B Moysich; Susanne K Kjær; Estrid Høgdall; Allan Jensen; Joellen M Schildkraut; Andrew Berchuck; Daniel W Cramer; Elisa V Bandera; Nicolas Wentzensen; Joanne Kotsopoulos; Steven A Narod; Catherine M Phelan; John R McLaughlin; Hoda Anton-Culver; Argyrios Ziogas; Celeste L Pearce; Anna H Wu; Kathryn L Terry
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-15       Impact factor: 4.254

3.  Menstrual pain and epithelial ovarian cancer risk.

Authors:  Ana Babic; Daniel W Cramer; Linda J Titus; Shelley S Tworoger; Kathryn L Terry
Journal:  Cancer Causes Control       Date:  2014-09-05       Impact factor: 2.506

4.  Contraceptive methods and ovarian cancer risk among Chinese women: A report from the Shanghai Women's Health Study.

Authors:  Zhezhou Huang; Yutang Gao; Wanqing Wen; Honglan Li; Wei Zheng; Xiao-Ou Shu; Alicia Beeghly-Fadiel
Journal:  Int J Cancer       Date:  2015-01-21       Impact factor: 7.396

5.  Reproductive factors and incidence of epithelial ovarian cancer: a Norwegian prospective study.

Authors:  G Albrektsen; I Heuch; G Kvåle
Journal:  Cancer Causes Control       Date:  1996-07       Impact factor: 2.506

Review 6.  Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies.

Authors:  Leo J Schouten; Christine Rivera; David J Hunter; Donna Spiegelman; Hans-Olov Adami; Alan Arslan; W Lawrence Beeson; Piet A van den Brandt; Julie E Buring; Aaron R Folsom; Gary E Fraser; Jo L Freudenheim; R Alexandra Goldbohm; Susan E Hankinson; James V Lacey; Michael Leitzmann; Annekatrin Lukanova; James R Marshall; Anthony B Miller; Alpa V Patel; Carmen Rodriguez; Thomas E Rohan; Julie A Ross; Alicja Wolk; Shumin M Zhang; Stephanie A Smith-Warner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-04-01       Impact factor: 4.254

Review 7.  Perineal talc use and ovarian cancer: a critical review.

Authors:  Joshua E Muscat; Michael S Huncharek
Journal:  Eur J Cancer Prev       Date:  2008-04       Impact factor: 2.497

8.  Oral contraceptives and the risk of all cancers combined and site-specific cancers in Shanghai.

Authors:  Karin A Rosenblatt; Dao L Gao; Roberta M Ray; Zakia C Nelson; Karen J Wernli; Wenjin Li; David B Thomas
Journal:  Cancer Causes Control       Date:  2008-08-15       Impact factor: 2.506

9.  Attributable causes of breast cancer and ovarian cancer in china: reproductive factors, oral contraceptives and hormone replacement therapy.

Authors:  Li Li; Jia Ji; Jian-Bing Wang; Mayineur Niyazi; You-Lin Qiao; Paolo Boffetta
Journal:  Chin J Cancer Res       Date:  2012-03       Impact factor: 5.087

10.  Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls.

Authors:  Kathryn L Terry; Stalo Karageorgi; Yurii B Shvetsov; Melissa A Merritt; Galina Lurie; Pamela J Thompson; Michael E Carney; Rachel Palmieri Weber; Lucy Akushevich; Wei-Hsuan Lo-Ciganic; Kara Cushing-Haugen; Weiva Sieh; Kirsten Moysich; Jennifer A Doherty; Christina M Nagle; Andrew Berchuck; Celeste L Pearce; Malcolm Pike; Roberta B Ness; Penelope M Webb; Mary Anne Rossing; Joellen Schildkraut; Harvey Risch; Marc T Goodman
Journal:  Cancer Prev Res (Phila)       Date:  2013-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.